TRAIL-expressing cell membrane nanovesicles as an anti-inflammatory platform for rheumatoid arthritis therapy
Graphical abstract
TRAIL-UVECs derived cell membrane was extracted and coated onto the HCQ-PLGA nanoparticles (TU-NPs), which inherit the source cell membrane receptors and TRAIL RA targeting ability. Due to the existence of TRAIL and inflammatory cytokines receptors, TU-NPs can actively target the inflamed joints and active macrophages to delivery antirheumatic drugs and neutralize the secreted cytokines, thus protect the cartilage and bone from erosion and destruction, and alleviate the progression of RA.
Introduction
Rheumatoid arthritis (RA) is one of the most devastating autoimmune disease with systemic inflammation and progressive disability, causing a serious threat to human health [1,2]. It primarily involves inflammatory cells infiltration, pannus formation, bone erosion and cartilage destruction [3,4]. At present, the precise mechanism of RA is still unknown. The main clinical agents for RA treatment currently are disease-modifying antirheumatic drugs (DMARDs) including anti-inflammatory biologics and synthetic small chemicals [5,6], but it commonly brings severe adverse effects such as osteoporosis, liver function failure and even lymphoma due to its nonspecific targeting and the complexity of inflammatory network [7,8]. Despite much progress has been made in treating RA, notably with the application of biologic DMARDs that target interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-α) or CD20 [[9], [10], [11]], the recent therapies still remain insufficient. One of the reasons for the dilemma is that the production of inflammatory cytokines in RA is a complexed system determined by numerous synovial infiltrated cells. Even a therapeutic blockade of one cytokine may not be enough to relieve its symptoms [12,13]. In clinics, chemical synthetic or biologic DMARDs have only partial therapeutic response for a large proportion of patients [[14], [15], [16], [17]]. Therefore, there is an urgent need to develop a novel anti-inflammatory strategy or drug delivery system to improve the therapeutic index and alleviate the adverse effects of RA treatment [[18], [19], [20], [21]].
Nowadays, with the advancement of cell membrane-based nanotechnology, cell membrane-coated nanoparticles (NPs) have been developed as a practical therapeutic platform [13,22,23]. In addition to achieving high drug accumulation in the target sites, cell membrane-coated NPs can efficaciously reduce the elimination and enhance the circulation time of nanoparticles [24,25]. Furthermore, the combined NPs are manufactured by surface coating natural cell membranes onto synthesized NPs and can mimic the source cells, which empowers them with the ability to bind and neutralize multitudinous and intricate pathological factors [13,26]. For example, cancer cell membrane-coated NPs have been used for homologous targeting to deliver antineoplastic drugs, improve the intravital half-time of drugs and decrease the toxicity on normal tissues [26,27]. Moreover, erythrocyte membrane- or macrophage-derived NPs have been widely used to absorb toxins during the period of exogenous bacterial infection and pathological autoantibodies that would otherwise cause serious autoimmune disease [28].
Encouraged by the progress of cell membrane based-camouflaged nanotechnology in biotherapies, we proposed a strategy that uses cell- mimicking NPs as an anti-inflammatory platform to address the challenges of RA treatment. Furthermore, decorating cell membranes with specific ligands that target inflammatory tissues or cells may enhance the drug delivery efficacy [24,29]. Nonetheless, gene engineering is a versatile platform that can be used to specifically express the targeting ligand onto the cell membrane without interfering with the existed membrane proteins, whereas chemical modification is hardly to achieve it. Herein, we developed a flexible approach to express tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) onto the cell membrane to target the actived M1 macrophages in the inflammatory sites of RA. Among the inflammatory cells, inflammatory M1 macrophages play a crucial role in the progression of RA because it can subsequently release inflammatory cytokines and chemokines to activate or recruit other immune cells [18,19]. Moreover, M1 macrophages can also adhere to the pannus of inflamed vascular tissue and participate in endothelium and synovium inflammation in the synovial joint environment, which ultimately cause bone erosion and cartilage destruction [20,21]. Because of the upregulated death receptor-5 (DR5) [30,31], TRAIL-expressing cell membrane-coated NPs could induce apoptosis of M1 macrophages while simultaneously targeting delivery of antirheumatic drugs to inflammatory tissues.
In this study, considering the fact that several inflammatory cytokines such as TNF-α can bind its receptor on the vascular endothelial cell to promote the formation of pannus, which is responsible for perpetuating RA progression [32,33], we prepared umbilical vein endothelial cell (UVEC) membrane-coated drug loaded NPs and functionalized them with inflammation-targeting ligands TRAIL (TU-NPs) through genetic bioengineering for antirheumatic drugs delivery. Notably, we chose hydroxychloroquine (HCQ), a first-line antirheumatic drug with low adverse effects, as a model payload to synthesize HCQ -NPs, U-NPs and TU-NPs. The capacity of TU-NPs for inducing differentiated M1 macrophage apoptosis was identified with immunofluorescence (IF), and neutralizing the inflammatory cytokines was evaluated by ELISA. We also compared TU-NP targeting ability to RA with that of bare U-NPs through advanced imaging technology. Finally, the therapeutic efficacy of TU-NPs was evaluated in the collagen-induced arthritis (CIA) mouse model.
Section snippets
Compounds and chemical reagents
Phorbol-12-myristate-13-acetate (PMA), Lipopolysaccharide (LPS) and hydroxychloroquine (HCQ) were purchased from Medchemexpress. Indocyanine Green-NHS ester (ICG-NHS) was bought from Ruixi Biological Technology. Glutaraldehyde and paraformaldehyde were purchased from Macklin. PMA and LPS were respectively dissolved and diluted to the desired concentration in vitro studies. HCQ was dissolved with phosphate buffer saline (PBS) to a desired concentration.
Cell lines and culture
The human umbilical vein endothelial cell
Nanoparticle preparation and characterization
To prepare RA joint targeting TU-NPs, gene engineering was used to construct TRAIL stably expressing UVECs, and the plasma membrane was extracted and purified to coat the synthesized HCQ-PLGA cores (Fig. 1A). Immunofluorescence and western blotting results both showed that TRAIL-GFP was successfully anchored onto the cell membrane (Fig. 1B and Fig. S1) which endowed the membrane with the ability of targeting to the DR5 overexpressed on the surface of inflamed macrophages. Also, the extracted
Conclusions
In this work, DR5 was found to overexpress in the inflamed tissues or infiltrated immune cells in RA microenvironment by analyzing the synovium fluid from RA patients and the induced inflammatory M1 macrophages. Thereby, TRAIL-stably-expressing UVECs were constructed by gene engineering, and TRAIL-anchored UVECs membrane coated HCQ-NPs (TU-NPs) were fabricated to target inflamed tissues and absorb the inflammatory cytokines in the microenvironment of RA. In addition, TU-NPs can largely
Declaration of Competing Interest
The authors report no conflicts of interest.
Acknowledgements
The work was supported by the National Natural Science Foundation of China (U1705281, 81925019, 81422023, 81871404, 81860386 and 81603015), the National Key Research and Development Program of China (2017YFA0205201 and 2018YFC1105900), the Fifth batch of special experts in Guangxi, the Fundamental Research Funds for the Central Universities (20720190088), and the Program for New Century Excellent Talents in University, China (NCET-13-0502).
References (45)
- et al.
Rheumatoid arthritis
Lancet
(2016) - et al.
Novel treatment strategies in rheumatoid arthritis
Lancet
(2017) - et al.
New therapies for treatment of rheumatoid arthritis
Lancet
(2007) - et al.
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis
Am. J. Pathol.
(2001) - et al.
Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases
Autoimmun. Rev.
(2019) - et al.
Human osteoarthritic synovium impacts chondrogenic differentiation of mesenchymal stem cells via macrophage polarisation state
Osteoarthr. Cartil.
(2014) - et al.
A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery
J. Control. Release
(2017) - et al.
Hyaluronan nanoparticles bearing gamma-secretase inhibitor: in vivo therapeutic effects on rheumatoid arthritis
J. Control. Release
(2014) - et al.
Cartilage-targeting and dual MMP-13/pH responsive theranostic nanoprobes for osteoarthritis imaging and precision therapy
Biomaterials
(2019) - et al.
Heterogeneity of the cytokinome in undifferentiated arthritis progressing to rheumatoid arthritis and its change in the course of therapy. Move toward personalized medicine
Cytokine
(2017)
Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis
Clin. Chim. Acta
Nanotherapeutics relieve rheumatoid arthritis
J. Control. Release
The pathogenesis of rheumatoid arthritis
N. Engl. J. Med.
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Nat. Rev. Rheumatol.
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
Ann. Rheum. Dis.
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Ann. Rheum. Dis.
Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand
Arthritis Rheum.
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Ann. Rheum. Dis.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
N. Engl. J. Med.
A randomised trial evaluating anakinra in early active rheumatoid arthritis
Clin. Exp. Rheumatol.
Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: a literature review
Int. J. Rheum. Dis.
Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis
Nat. Nanotechnol.
Cited by (61)
Nanomedical approaches in the realm of rheumatoid arthritis
2023, Ageing Research ReviewsNanomaterial-assisted theranosis of bone diseases
2023, Bioactive MaterialsLiver fibrosis therapy based on biomimetic nanoparticles which deplete activated hepatic stellate cells
2023, Journal of Controlled Release
- 1
These authors contributed equally to this work.